Septerna

At the Cantor Fitzgerald Healthcare Conference, Septerna presented an expanded pipeline based on its GPCR discovery platform and emphasized a strong balance sheet with USD 516 million in cash to fund the company through at least 2029. Lead program SEP-479 (oral PTH receptor agonist) is in Phase I with preparations for Phase II; SEP-631 (MRGPRX2 inhibitor) is shifting from large-scale CSU studies to smaller, biomarker-driven trials. A TSH receptor program is approaching candidate selection, and an early osteoporosis program plus a collaboration with Novo Nordisk round out the long-term strategy. » More on de.investing.com

At the Wells Fargo Healthcare Conference Septerna presented its Native Complex Platform, which the company says unlocks hard-to-reach GPCR targets and has repeatedly identified suitable molecules. The lead program SEP-479 (oral, PTH agonist) is on schedule; full Phase I data are expected to be released in Q1 2025. The company emphasizes capital-efficient development plans for MRGPRX2 (SEP-631) and a TSH receptor program, expects multiple catalysts in 2027, and cites the USD 195 million upfront from Novo Nordisk plus reimbursed R&D costs as a balance-sheet strengthening. Management flagged early safety risks (SEP-786 discontinued) and highlighted enhanced risk-mitigation measures such as early toxicity studies and backup candidates. » More on de.investing.com

Septerna’s stock reached an all-time high of $50 and is currently trading at $49.47, with a market capitalization of about $2.28 billion. The stock rose 326% over the past year and 71% year-to-date; InvestingPro rates the current level as fair. Analysts updated price targets following progress with SEP-479: H.C. Wainwright raised its target to $60 and reiterated a buy rating, Stifel set a $49 target, while Guggenheim later cut its target to $45 after negative industry signals. » More on de.investing.com